Drugs / pVAX/L523S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00062907 | May 2003 → ? | non-small cell lung carcinoma | Corixa Corporation | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pVAX/L523S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00062907 ↗ |
| Modality | Vaccine | “The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients...” NCT00062907 ↗ |